Sprycel beats Gleevec in pivotal trial in newly diagnosed CML
This article was originally published in Scrip
Bristol-Myers Squibb's second-generation BCR-ABL inhibitor Sprycel (dasatinib) showed superior complete response rates to the standard of care in chronic phase chronic myeloid leukaemia (CML), Novartis's Gleevec (imatinib), and could become a new first-line treatment option in the disease, according to the Phase III DASISION data presented at the ASCO meeting in Chicago and simultaneously published in the NEJM.
You may also be interested in...
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.